Non-enzymatic pretreatment of nerve agent (soman) poisoning: A brief state-of-the-art review

Toxicology Letters

Volumn 206, Issue 1, 2011, Pages 35-40

  van Helden, Herman P M ^a   Joosen, Marloes J A ^a   Philippens, Ingrid H C ^b  

^a TNO   (Netherlands)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Bupropion; Galantamine; Physostigmine; Pretreatment; Procyclidine; Scopolamine

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; AMFEBUTAMONE; ATROPINE; BENZODIAZEPINE; BRETAZENIL; CARAMIPHEN; DIAZEPAM; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; IMIDAZENIL; PHYSOSTIGMINE; PROCYCLIDINE; PYRIDOSTIGMINE; RIVASTIGMINE; SCOPOLAMINE; SOMAN;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; BINDING AFFINITY; BRAIN DAMAGE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTOXICATION; DRUG SAFETY; ENZYME REACTIVATION; HEAT STRESS; HUMAN; MENTAL PERFORMANCE; MONOTHERAPY; NERVE AGENT POISONING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SEIZURE; SINGLE DRUG DOSE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIDOTES; BRAIN; CHEMICAL WARFARE AGENTS; CHOLINESTERASE INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; NEUROTOXICITY SYNDROMES; PROTEIN BINDING; RECEPTORS, CHOLINERGIC; RECEPTORS, GLUTAMATE; SOMAN;

CAVIA;

EID: 80051817156     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.04.021     Document Type: Review

References (34)

1. Albuquerque E.X., Pereira E.F., Aracava Y., Fawcett W.P., Oliveira M., Randall W.R., Hamilton T.A., Kan R.K., Romano J.A., Adler M. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(35):13220-13225.
2. Albuquerque E.X., Pereira E.F., Alkondon M., Rogers S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 2009, 89(January (1)):73-120. (Review).
3. Aracava Y., Pereira E.F., Akkerman M., Adler M., Albuquerque E.X. Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. J. Pharmacol. Exp. Ther. 2009, 331(3):1014-1024.
4. Bajgar J. Prophylaxis against organophosphorus poisoning. J. Med. Chem. Def. 2004, 1:1-16. (E journal). http://jmedchemdef.org/current.html.
5. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int. J. Clin. Pract. 2003, 57(3):219-223.
6. Friedman A., Kaufer D., Shemer J., Hendler I., Soreq H., Tur-Kaspa I. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nat. Med. 1996, 2:1382-1385.
7. Golomb B.A. Acetylcholinesterase inhibitors and Gulf War illnesses. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(11):4295-4300.
8. Gullapalli R.P., Aracava Y., Zhuo J., Helal Neto E., Wang J., Makris G., Merchenthaler I., Pereira E.F., Albuquerque E.X. Magnetic resonance imaging reveals that galantamine prevents structural brain damage induced by an acute exposure of guinea pigs to soman. Neurotoxicology 2010, 31(1):67-76.
9. Hartvig P., Wiklund L., Lindström B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol. Scand. 1986, 30(2):177-182.
10. Haug K.H., Myhrer T., Fonnum F. The combination of donepezil and procyclidine protects against soman-induced seizures in rats. Toxicol. Appl. Pharmacol. 2007, 220(2):156-163.
11. Joosen M.J., Smit A.B., van Helden H.P. Treatment efficacy in a soman-poisoned guinea pig model: added value of physostigmine?. Arch. Toxicol. 2011, 85(3):227-237.
12. Inns R.H., Leadbeater L. The efficacy of bispyridinium derivatives in the treatment of organophosphonate poisoning in the guinea-pig. J. Pharm. Pharmacol. 1983, 35(7):427-433.
13. Kadriu B., Guidotti A., Costa E., Auta J. Imidazenil, a non-sedating anticonvulsant benzodiazepine, is more potent than diazepam in protecting against DFP-induced seizures and neuronal damage. Toxicology 2009, 256(3):164-174.
14. Kassa J., Vachek J. A comparison of the efficacy of pyridostigmine alone and the combination of pyridostigmine with anticholinergic drugs as pharmacological pretreatment of tabun-poisoned rats and mice. Toxicology 2002, 177(2-3):179-185.
15. Lallement G., Baille V., Baubichon D., Carpentier P., Collombet J.M., Filliat P., Foquin A., Four E., Masqueliez C., Testylier G., Tonduli L., Dorandeu F. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 2002, 23(1):1-5. (Review).
16. Levy A., Brandeis R., Meshulam Y. Transdermal physostigmine and scopolamine: human studies. Proceedings of Medical Defense BioScience Review, vol. 1 1996, 505-516. US Army medical Research Institute of Chemical, Aberdeen Proving Ground, MD.
17. Meshulam Y., Davidovici R., Wengier A., Levy A. Prophylactic transdermal treatment with physostigmine and scopolamine against soman intoxication in guinea-pigs. J. Appl. Toxicol. 1995, 15(4):263-266.
18. Muggleton N.G., Bowditch A.P., Crofts H.S., Scott E.A., Pearce P.C. Assessment of a combination of physostigmine and scopolamine as pretreatment against the behavioural effects of organophosphates in the common marmoset (Callithrix jacchus). Psychopharmacology (Berl.) 2003, 166(3):212-220.
19. Myhrer T., Nguyen N.H., Andersen J.M., Aas P. Protection against soman-induced seizures in rats: relationship among doses of prophylactics, soman, and adjuncts. Toxicol. Appl. Pharmacol. 2004, 196(3):327-336.
20. Myhrer T., Enger S., Aas P. Cognitive side effects in rats caused by pharmacological agents used to prevent soman-induced lethality. Eur. J. Pharmacol. 2004, 483(2-3):271-279.
21. Myhrer T., Enger S., Aas P. Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats. Pharmacol. Biochem. Behav. 2008, 89(4):633-638.
22. Myhrer T. Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology 2010, 31(6):629-638.
23. Pereira E.F., Hilmas C., Santos M.D., Alkondon M., Maelicke A., Albuquerque E.X. Unconventional ligands and modulators of nicotinic receptors. J. Neurobiol. 2002, 53(4):479-500. Review.
24. Philippens I.H., Wolthuis O.L., Busker R.W., Langenberg J.P., Melchers B.P. Side effects of physostigmine as a pretreatment in guinea pigs. Pharmacol. Biochem. Behav. 1996, 55(1):99-105.
25. Philippens I.H., Busker R.W., Wolthuis O.L., Olivier B., Bruijnzeel P.L., Melchers B.P. Subchronic physostigmine pretreatment in guinea pigs: effective against soman and without side effects. Pharmacol. Biochem. Behav. 1998, 59(4):1061-1067.
26. Philippens I.H., Melchers B.P., Olivier B., Bruijnzeel P.L. Scopolamine augments the efficacy of physostigmine against soman poisoning in guinea pigs. Pharmacol. Biochem. Behav. 2000, 65(1):175-182.
27. Philippens I.H., Vanwersch R.A., Groen B., Olivier B., Bruijnzeel P.L., Melchers B.P. Subchronic physostigmine pretreatment in marmosets: absence of side effects and effectiveness against soman poisoning with negligible postintoxication incapacitation. Toxicol. Sci. 2000, 53(1):84-91.
28. Rauhut A.S., Dwoskin L.P., Bardo M.T. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob. Res. 2005, 7(6):901-907.
29. Raveh L., Weissman B.A., Cohen G., Alkalay D., Rabinovitz I., Sonego H., Brandeis R. Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. Neurotoxicology 2002, 23(1):7-17.
30. Research Advisory Committee on Gulf War Veterans' Illnesses. Report 2008. http://www.va.gov/RAC-GWVI.
31. Roy M.J., Kraus P.L., Seegers C.A., Young S.Y., Kamens D.R., Law W.A., Cherstniakova S.A., Chang D.N., Cooper J.A., Sato P.A., Matulich W., Krantz D.S., Cantilena L.R., Deuster P.A. Pyridostigmine, diethyltoluamide, permethrin, and stress: a double-blind, randomized, placebo-controlled trial to assess safety. Mayo Clin. Proc. 2006, 81(10):1303-1310.
32. Tashma Z., Raveh L., Liani H., Alkalay D., Givoni S., Kapon J., Cohen G., Alcalay M., Grauer E. Bretazenil, a benzodiazepine receptor partial agonist, as an adjunct in the prophylactic treatment of OP poisoning. J. Appl. Toxicol. 2001, 21(Suppl. 1):S115-S119.
33. Thomsen T., Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci. 1990, 46(21):1553-1558.
34. Tuovinen K., Hänninen O. Protection of mice against soman by pretreatment with eptastigmine and physostigmine. Toxicology 1999, 139(3):233-241.